KRAS and colorectal carcinoma: The OncoCartaTM panel is a set of pre-designed and pre-validated assays by the parallel analysis of 238 possible mutations in 19 clinically relevant genes with as little as 500 ng DNA per sample, including frequent mutated genes such as KRAS, NRAS, BRAF and PIK3CA, which are most clinically relevant for CRC.